Trials / Recruiting
RecruitingNCT07037420
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose Range-finding, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALXN2420, a Growth Hormone Receptor Antagonist, Administered Subcutaneously in Combination With Somatostatin Analogs in Adult Participants With Acromegaly
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog (SSA) therapy to adult participants with acromegaly.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALXN2420 | ALXN2420 will be administered via subcutaneous (SC) injection |
| DRUG | Placebo | Placebo will be administered via SC injection. |
Timeline
- Start date
- 2025-10-28
- Primary completion
- 2027-01-08
- Completion
- 2027-11-11
- First posted
- 2025-06-25
- Last updated
- 2026-04-07
Locations
45 sites across 11 countries: United States, Argentina, Brazil, China, Denmark, Hungary, Italy, Lithuania, Netherlands, Poland, Romania
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07037420. Inclusion in this directory is not an endorsement.